Literature DB >> 14738454

Expression of CTLA-4 in nonhuman primate lymphocytes and its use as a potential target for specific immunotoxin-mediated apoptosis: results of in vitro studies.

G L Palmisano1, P L Tazzari, E Cozzi, A Bolognesi, L Polito, M Seveso, E Ancona, F Ricci, R Conte, F Stirpe, G B Ferrara, M P Pistillo.   

Abstract

T-cell-mediated immunoregulation is one of the main mechanisms implicated in induction and maintenance of transplantation tolerance. In this regard, deletion or modulation of xeno/alloantigen-specific T cells, as well as blocking of their interactions with other cell populations, are currently being pursued for tolerance induction in humans as well as nonhuman primates. In order to investigate whether cytotoxic T-lymphocyte antigen-4 (CTLA-4) may represent a suitable target for a T cell depletion approach in nonhuman primate models, we analysed CTLA-4 expression in peripheral blood mononuclear cells (PBMCs) from nonhuman primates and the potential role of two anti-CTLA-4 saporin-conjugated immunotoxins. The analysis was performed in PBMCs from 8 cynomolgus monkeys from Philippines and from Mauritius both at protein level by flow cytometry and at transcriptional level by RT-PCR. In addition, the apoptotic role of the immunotoxins was investigated. The results showed that CTLA-4 was expressed at variable levels depending on the origin of the cynomolgus monkeys and the resting or activated cell condition. CTLA-4 was not expressed on resting Mauritius PBMCs and showed a lower up-regulation upon PMA/PHA activation compared to the Philippines PBMCs that expressed CTLA-4 also before activation. Two CTLA-4 RNA transcripts (672 and 550 bp) were detected with levels variations after cell stimulation. Two anti-CTLA-4 immunotoxins induced in vitro apoptosis of activated PBMCs from both sources of cynomolgus monkeys. This is the first report that documents CTLA-4 expression both at protein and transcriptional level by nonhuman primate PBMCs and provides novel perspectives of xeno/allograft rejection immunotherapy based on CTLA-4 targeting.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14738454      PMCID: PMC1808938          DOI: 10.1111/j.1365-2249.2003.02382.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  33 in total

1.  A soluble form of CTLA-4 generated by alternative splicing is expressed by nonstimulated human T cells.

Authors:  G Magistrelli; P Jeannin; N Herbault; A Benoit De Coignac; J F Gauchat; J Y Bonnefoy; Y Delneste
Journal:  Eur J Immunol       Date:  1999-11       Impact factor: 5.532

2.  CTLA-4 and CD28 mRNA are coexpressed in most T cells after activation. Expression of CTLA-4 and CD28 mRNA does not correlate with the pattern of lymphokine production.

Authors:  G J Freeman; D B Lombard; C D Gimmi; S A Brod; K Lee; J C Laning; D A Hafler; M E Dorf; G S Gray; H Reiser
Journal:  J Immunol       Date:  1992-12-15       Impact factor: 5.422

Review 3.  Transplantation of discordant xenografts: a review of progress.

Authors:  J L Platt; G M Vercellotti; A P Dalmasso; A J Matas; R M Bolman; J S Najarian; F H Bach
Journal:  Immunol Today       Date:  1990-12

4.  Inhibition of anti-Gal IgG binding to porcine endothelial cells by synthetic oligosaccharides.

Authors:  U Galili; K L Matta
Journal:  Transplantation       Date:  1996-07-27       Impact factor: 4.939

5.  CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates.

Authors:  A D Kirk; D M Harlan; N N Armstrong; T A Davis; Y Dong; G S Gray; X Hong; D Thomas; J H Fechner; S J Knechtle
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-05       Impact factor: 11.205

6.  CTLA-4 can function as a negative regulator of T cell activation.

Authors:  T L Walunas; D J Lenschow; C Y Bakker; P S Linsley; G J Freeman; J M Green; C B Thompson; J A Bluestone
Journal:  Immunity       Date:  1994-08       Impact factor: 31.745

7.  Anti-pig IgM antibodies in human serum react predominantly with Gal(alpha 1-3)Gal epitopes.

Authors:  M S Sandrin; H A Vaughan; P L Dabkowski; I F McKenzie
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-01       Impact factor: 11.205

8.  Production of alpha 1,3-galactosyltransferase-deficient pigs.

Authors:  Carol J Phelps; Chihiro Koike; Todd D Vaught; Jeremy Boone; Kevin D Wells; Shu-Hung Chen; Suyapa Ball; Susan M Specht; Irina A Polejaeva; Jeff A Monahan; Pete M Jobst; Sugandha B Sharma; Ashley E Lamborn; Amy S Garst; Marilyn Moore; Anthony J Demetris; William A Rudert; Rita Bottino; Suzanne Bertera; Massimo Trucco; Thomas E Starzl; Yifan Dai; David L Ayares
Journal:  Science       Date:  2002-12-19       Impact factor: 47.728

9.  Human CD25+CD4+ T suppressor cell clones produce transforming growth factor beta, but not interleukin 10, and are distinct from type 1 T regulatory cells.

Authors:  Megan K Levings; Romina Sangregorio; Claudia Sartirana; Anna Lisa Moschin; Manuela Battaglia; Paul C Orban; Maria-Grazia Roncarolo
Journal:  J Exp Med       Date:  2002-11-18       Impact factor: 14.307

10.  CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.

Authors:  M F Krummel; J P Allison
Journal:  J Exp Med       Date:  1995-08-01       Impact factor: 14.307

View more
  4 in total

Review 1.  Profile of ipilimumab and its role in the treatment of metastatic melanoma.

Authors:  Sapna P Patel; Scott E Woodman
Journal:  Drug Des Devel Ther       Date:  2011-12-16       Impact factor: 4.162

Review 2.  Immunotoxins constructed with ribosome-inactivating proteins and their enhancers: a lethal cocktail with tumor specific efficacy.

Authors:  Roger Gilabert-Oriol; Alexander Weng; Benedicta von Mallinckrodt; Matthias F Melzig; Hendrik Fuchs; Mayank Thakur
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

Review 3.  Hyperuricaemia, Xanthine Oxidoreductase and Ribosome-Inactivating Proteins from Plants: The Contributions of Fiorenzo Stirpe to Frontline Research.

Authors:  Andrea Bolognesi; Massimo Bortolotti; Maria Giulia Battelli; Letizia Polito
Journal:  Molecules       Date:  2017-01-27       Impact factor: 4.411

4.  Immune checkpoint blockade enhances chemophototherapy in a syngeneic pancreatic tumor model.

Authors:  Sanjana Ghosh; Xuedan He; Wei-Chiao Huang; Jonathan F Lovell
Journal:  APL Bioeng       Date:  2022-09-23
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.